Biomarkers for Diabetes Complications: The Results of Several Clinical Studies
Diabetes is a common metabolic disorder. Its microvascular and macrovascular complications contribute to death, disabilities, and reduction in life expectancy in diabetes. It is a costly disease, and affects not only the patient and family, but also the public health, communities and society. It takes an increasing proportion of the national health care expenditure. The prevention of the development of diabetes and its complications is a major concern. Biomarkers have been investigated for understanding the mechanisms of the development and progression of diabetic complications. In this paper, the biomarkers which are recommended in the clinical practice and laboratory medicine guidelines, and which have been investigated for prediction or diagnosis of diabetes complications, have been reviewed. The results of several clinical studies will be summarized.
Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28 (9): 2130-5.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (6): 1615-25.
Marshall S, Flyvbjerg A. Prevention and early detection of vas cular complications of diabetes. BMJ 2006; 333: 475-80.
King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79 (8 Suppl): 1527-34.
Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010; 53 (2): 263-7.
Kolberg JA, Jörgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009; 32 (7): 1207-12.
Beisswenger PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2010. Doi: 10.1007/s00726-010-0784-z.
Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3 (2): 101-8.
Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011. doi:10.1016/j.semcdb.2011.02.015.
Takeuchi M, Takino J, Yamagishi S. Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol 2010; 1-12. doi:10.1155/2010/170393.
Lam CS, Benzie IF, Choi SW, Chan LY, Yeung VT, Woo GC. Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci 2011 Feb; 88 (2): 251-6.
Vicentini J, Valentini J, Grotto D, Paniz C, Roehrs M, Brucker N, et al. Association among microalbuminuria and oxidative stress biomarkers in patients with type 2 diabetes. J Investig Med 2011: 1-6.
Sharma RK, Rogojina AT, Chalam KV. Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor. Mol Vis 2009; 15: 60-9.
Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010; 10 (1): 37-42.
Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, et. al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009; 11 (1): 1-9.
Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010 Mar; 26 (3): 150-71.
Scott EM, Carter AM, Findlay JB. The application of proteomics to diabetes. Diab Vasc Dis Res 2005 May; 2 (2): 54-60.
Sundsten T, Eberhardson M, Göransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006; 12; 4: 22.
Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30 (3): 638-43.
Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM. The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2 (7-8): 997-1007.
Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19 (7): 1283-90.
Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20 (9): 2065-74.
Ameur RB, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Trans plant 2010; 25 (9): 2866-75.
Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes re search: moving from information to knowledge. Diabetes 2009 Nov; 58 (11): 2429-43.
Benito-Martín A, Ucero AC, Santamaría B, Lorz C, Kretzler M, Rastaldi MP, et al. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy. Nefrologia 2009; 29 (1): 13-19.
Meikle PJ, Tsorotes D, Barlow CK, Weir J, MacIntosh GL, Barber M, et al. Plasma lipidomic analysis for prediction of unstable coronary artery disease. [Abstract] Circulation 2010; 122: A15009.
Shi Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. Journal of Biomedical Research 2010; 24 (1): 6-15.
Sorensen CM, Ding J, Zhang Q, Alquier T, Zhao R, Mueller PW, Smith RD, Metz TO. Perturbations in the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus: lipidomics analysis of a Diabetes Antibody Standardization Program sample subset. Clin Biochem 2010; 43 (12): 948-56.
Priego-Capote F, Scherl A, Müller M, Waridel P, Lisacek F, Sanchez JC. Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010; 9 (3): 579-92.
Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON 1 poly morphisms, PON activity and diabetes complications. J Diabetes Complications 2006 Sep-Oct; 20 (5): 322-8.
Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-41.
Kazemi Arababadi M. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 2010 Oct; 4 (4): 302-6.
Balasubbu S, Sundaresan P, Rajendran A, Ramasamy K, Govindarajan G, Perumalsamy N, et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet 2010; 10 (11): 158.
Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, et al; DIABHYCAR and SURDIAGENE Study Groups. Association of ADIPOQ genetic variants and plas ma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 2010 Jul; 25 (7): 2231-7.
Jiang YD, Chang YC, Chiu YF, Chang TJ, Li HY, Lin WH, et al. SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes. BMC Med Genet 2010; 11: 126.
Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304 (8): 881-9.
Yang Y, Andresen BT, Yang K, Zhang Y, Li X, Li X, et al. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood) 2010; 235 (10): 1204-11.
Stankov K. Genetic predisposition for type 1 diabetes mellitus - The role of endoplasmic reticulum stress in human disease etiopathogenesis. Journal of Biomedical Biochemistry 2010; 29: 139-149.
Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011 Feb 9; 10(1):16.
Hamet P, Tremblay J. Will ADVANCE population genomic determinants improve upon biomarkers in predicting vascular complications of diabetes? Medicographia 2009; 31: 307-13.
Golubnitschaja O. Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA Journal 2010; 1: 3-12.
Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem 2011 Feb; 57 (2): 231-40.
American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33 (Suppl): S11-61.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, M, Kirkman S, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. DRAFT November 2010 Version. NACB: Laboratory Medicine Practice Guidelines (LMPG) http://www.aacc.org/members/nacb/lmpg/pages/default.aspx (Accessed: 2010). http://www.aacc.org/members/nacb/lmpg/pages/default.aspx
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Alan C, et al. National Evidence Based Guideline for Diag nosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.
Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, Akhtar MW. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 2010 Dec; 12 (12): 979-88.
DPK Ng. Human Genetics of Diabetic Retinopathy: Current Perspectives. Journal of Ophthalmology 2010: 1-6.
Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia (2011) 54: 803-11.
Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Invest 2010; 1 (3): 90-6.
Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33 (12): 2561-6.
Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. Hypertens 1998; 16: 2019-26.
Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Kohri K, et al. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med 2006; 23: 617-22.
Van der Zijl NJ, Hanemaaijer R, Tushuizen ME, Schindhelm RK, Boerop J, Rustemeijer C, et al. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy? Clin Biochem 2010; 43 (7-8): 635-9.
Oh JY. Serum cystatin C as a biomarker for predicting coronary artery disease in diabetes. Korean Diabetes J 2010; 34 (2): 84-5.
True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol 2009; 3 (4): 743-7.
Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, et al. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 2010; 33 (2): 252-7.
Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32 (2): 91-8.
Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci 2011; 341 (1): 28-32.
Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional Markers of Glycemia: Associations with microvascular conditions. Diabetes Care [Abstract]. 2011. doi: 10.2337/dc10-1945.